MISTMilestone Pharmaceuticals Inc.

Sign up free
⚡

Milestone presents data on etripamil for post-ablation PSVT - Investing.com

Investing.com · Nov 2, 1:44 PM

Market reactionShares fell 10% on Nov 5.

ChallengedLast material event Oct 9, 2026 · Updated Nov 2, 2026

CARDAMYST sales growth remains central despite encouraging prior-ablation subgroup results

Milestone Pharmaceuticals sells CARDAMYST, a nasal spray patients use themselves to stop sudden fast-heartbeat episodes (PSVT); it is approved in the U.S. and China.

Milestone's case depends on scaling CARDAMYST's U.S. PSVT launch as insurance coverage widens. Early prescriptions grew, but limited sales and launch spending keep financing pressure central. China approval adds partner milestones and potential royalties, while a European decision is expected in the first half of 2027. ReVeRA-301 is enrolling for AFib-RVR, offering expansion potential. Management expects cash to fund operations into the second half of 2027. The small RAPID prior-ablation subgroup adds clinical support without changing these commercial priorities.

Thesis checklist

2 risks need attention

Select a row for evidence
CARDAMYST sales accelerateAt riskNext: Look for prescription and revenue acceleration following the expansion in insurance coverage.

Why it is in this state

The evidence, what would weaken it and the source filing

Insurance coverage widensSupportedNext: Look for further payer additions and details on patients' practical access to treatment.

Why it is in this state

The evidence, what would weaken it and the source filing

ReVeRA-301 enrolls for a second indicationAwaiting evidenceNext: Look for treated-event accrual and a disclosed timetable for ventricular-rate and symptom results.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts until sales cover costsAt riskNext: Track operating cash use, sales growth and any revisions to management's funding outlook.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Does wider coverage translate into stronger CARDAMYST sales?

Tests: CARDAMYST sales accelerate

At the next quarterly commercial update.

Are prescriptions and revenue accelerating as wider insurance coverage reaches patients?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical
+7.4%Oct 9, 2026

CARDAMYST sales growth remains central despite encouraging prior-ablation subgroup results

ChallengedRegulatory
+2.5%Sep 3, 2026

CARDAMYST approved and launching, but a $28.6M quarterly net loss against an H2 2027 runway forces the commercial ramp to outpace the clock

ChallengedCommercial
-11.4%Aug 12, 2026

CARDAMYST approved and prescriptions accelerating, but burn-versus-revenue gap makes payer traction the make-or-break condition

IntactCommercial
-9.5%May 13, 2026

CARDAMYST's PSVT launch trajectory and AFib-RVR expansion define whether etripamil becomes a multi-indication antiarrhythmic franchise

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

PSVT
etripamil · 1 upcoming · 1 completed
Regulatory DecisionEU
H1 2027
Atrial fibrillation with rapid ventricular rate
etripamil · 2 upcoming · 1 completed
Phase 3 Data: ToplineReVeRA-301Pivotal
TBD
sNDA Submission
TBD
Paroxysmal supraventricular tachycardia
etripamil · 2 completed
PDUFA Decision
Reported Dec 15, 2025
NDA Resubmission
Reported Jun 16, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Milestone Pharmaceuticals (MIST) investment thesis intact?
It is under pressure. Readouts currently rates the Milestone Pharmaceuticals Thesis Challenged. CARDAMYST sales growth remains central despite encouraging prior-ablation subgroup results.
What is the next catalyst for Milestone Pharmaceuticals (MIST)?
The next dated event is EU regulatory decision for Etripamil, expected H1 2027, as stated by the company.
How long will Milestone Pharmaceuticals' cash last?
Milestone Pharmaceuticals has said its cash will fund operations into H2 2027 (guidance as of August 12, 2026). It reported $171 million in cash as of June 30, 2026.

Disease areas: Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

vs. direct competitors

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.